Clinical trials: Cyclophosphamide
Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
The purpose of this study is to see if the IRX-2 regimen and Durvalumab, will have a tolerable safety profile and will increase the intratumoral immune profile compared with the pretreatment tumors.
- Conditions
- Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT03381183
- Testing
- Durvalumab, IRX-2 Regimen
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Autologous Hematopoietic Stem Cell Transplantation, Conditioning
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT
The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Autologous Hematopoietic Stem Cell Transplantation, Conditioning, Multiple Myeloma
- Trial name
- NCT03385096
- Testing
- Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Rheumatoid Arthritis
A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis
WA16291 is a Phase IIa "proof-of-concept" study. The primary objective of this study is to determine the safety and efficacy of rituximab (a B cell depleting chimeric monoclonal antibody) used either as monotherapy or in…
- Trial name
- NCT02693210
- Testing
- Cyclophosphamide, Methotrexate
- Where
- 33 sites in Australia, Belgium and 9 more
- Volunteers
- 161 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma Multiforme
Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
Chimeric antigen receptor (CAR)-modified T cells can mediate long-term durable remissions in recurrent or refractory CD19+ B cell malignancies, and are a promising therapy to treat glioblastoma, which is the most dangerous and…
- Trial name
- NCT02844062
- Testing
- anti-EGFRvIII CAR T cells, cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Sanbo Brain Hospital
Idiopathic Pulmonary Fibrosis
Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a major event of IPF with an annual incidence between 5 and 10% and is responsible for the death of one third of IPF patients.
- Trial name
- EXAFIP (NCT02460588)
- Testing
- Cyclophosphamide, Corticosteroid (prednisolone)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma
Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002905
- Testing
- cyclophosphamide, didanosine, doxorubicin hydrochloride
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Malignant (Pleural) Mesothelioma
Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma
Earlier the investigators determined the safety and feasibility of tumor lysate-pulsed dendritic cells as therapeutic adjuvants in mesothelioma patients.
- Trial name
- PMR-MM-002 (NCT01241682)
- Testing
- DC + CTX
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Erasmus Medical Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005641
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Platinum-resistant Epithelial Ovarian Cancer
Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer
Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian cancer.
- Trial name
- AVALON (NCT05243524)
- Testing
- Maveropepimut-S, Cyclophosphamide 50mg
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 16 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Philadelphia Positive Acute Lymphoblastic Leukemia, Lymphoid Blastic Phase of Chronic Myeloid Leukemia
Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)
The aims of the study are to determine whether single agent imatinib (STI571; Glivec) is more effective as up-front remission induction therapy than conventional multi-agent induction chemotherapy for elderly patients with…
- Trial name
- NCT00199186
- Testing
- imatinib, vincristine, cyclophosphamide
- Where
- Germany
- Sponsor
- Johann Wolfgang Goethe University Hospital
Leukemia
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Alternating treatment with more than one drug may kill more cancer cells.
- Trial name
- NCT00003829
- Testing
- cyclophosphamide, fludarabine phosphate
- Where
- 17 sites in United States
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma, DLBCL
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy
Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21.
- Conditions
- Lymphoma, DLBCL, Follicular Lymphoma
- Trial name
- Epi-RCHOP (NCT02889523)
- Testing
- Tazemetostat, Rituximab, Cyclophosphamide
- Where
- 31 sites in Belgium, France
- Volunteers
- 214 people
- Sponsor
- The Lymphoma Academic Research Organisation
Metastatic Non Small Cell Lung Cancer
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
- Trial name
- NCT04614103
- Testing
- LN-145
- Where
- 71 sites in United States, Australia and 10 more
- Volunteers
- 170 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Breast Cancer
Tamoxifen in Treating Women With High-Risk Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002542
- Testing
- CMF regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 48 sites in Canada
- Volunteers
- 672 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer, Triple Negative Breast Neoplasms
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Primary aim: To compare the effect on pathologic complete response (pCR) rate of adding capecitabine to carboplatin based preoperative chemotherapy in early ER-negative and HER2-negative breast cancer.
- Trial name
- NCT04335669
- Testing
- epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab, epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab
- Where
- 24 sites in Denmark, Sweden
- Volunteers
- 325 people
- Sponsor
- Lund University Hospital
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (DA-EPOCH) works in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Trial name
- NCT03023046
- Testing
- Cyclophosphamide, Dasatinib, Doxorubicin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Washington
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, ifosfamide, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- GemTIP (NCT00551122)
- Testing
- filgrastim, lenograstim, pegfilgrastim
- Where
- 3 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Southampton
Multiple Myeloma Stage I
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation
The best induction protocol to eligible multiple myeloma patients was not established. Combination of three drugs demonstrated better outcomes than two drugs combo.
- Trial name
- MAXDARA (NCT03792620)
- Testing
- Cyclo Thal Dex Daratumumab
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Advanced Solid Tumor, Tumor Associated Lymph Node T Cell
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
A total of 17 to 23 participants are anticipated to be enrolled in the Phase I clinical trial, which is further divided into two distinct parts: one part involves single-agent cell therapy, while the other entails a combination…
- Conditions
- Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
- Trial name
- TAL-T (NCT06302062)
- Testing
- Tumor Associated Lymph node T cell, cyclophosphamide, IL-2
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
Breast Cancer
Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer
The rationale of this randomized phase II study is to investigate the feasibility of sequenced densified FEC and docetaxel based regimens in patients with primary operable high-risk breast cancer.
- Trial name
- NCT00256360
- Testing
- dose dense with neulasta
- Where
- Belgium
- Volunteers
- 117 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven